
News|Articles|August 1, 2002
Voriconazole: A novel azole antifungal agent (PDF)
In late May, voriconazole (Vfend) received approval for the treatment of invasive aspergillosis and as salvage therapy for treatment of Scedosporium apiospermum and Fusarium infections. In addition to these infections, voriconazole has excellent invitro activity against both Candida and Aspergillus species, including good activity against fluconazole- and itraconazole-resistant species. This Focus article reviews the antifungal's pharmacology, pharmacokinetics, efficacy in clinical trials, safety, dosing, price, and place in therapy.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Insights from the AMCP Nexus 2025 Meeting
2
The Shift in Star Ratings That Health Plans Can't Ignore
3
Clinical and Economic Impact of OAB Symptoms in Men Receiving Pharmacological Treatment for BPH
4
MHE Week in Review – HPV Vaccine Still Effective, Dry Eye Disease Lacks Effective Treatments and More
5

















































